June 11, 2008
Meditor Pharmaceuticals Ltd. announced today the results of the Phase II, Randomized Double Blind, Placebo-Controlled Dose-Escalating Study in Migraine patients. 
May 12, 2008
Dr. Schachner has been a member of Meditor's Scientific Advisory Board
since 2001 and will now take a more active role in the Clinical Development
program
November 6, 2007
A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
Meditor Pharmaceuticals Ltd. is a biopharmaceutical company dedicated to the development and commercialization of proprietary products for the therapeutic management of acute and chronic hypotension and hypotension related disorders.
Meditor’s clinical development program is focused on lead compound, MTR104, a synthetic small molecule for the treatment of three main medical targets. Three formulations of the lead compound are used in the following indications:
- MTR107 (i.v. formulation) for Intradialytic hypotension,
- MTR106 (immediate release oral tablet formulation) for Migraine, and;
- MTR105 (i.v. formulation) for the treatment of hypotension associated with Cardiac surgery
In 2003, the FDA granted Meditor IND (Investigational New Drug) number 66,505 authorizing the beginning of two separate Phase II clinical trials: MTR107 for the treatment of Intradialytic hypotension and MTR105 for the treatment of hypotension associated with Cardiac surgery.